Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: Thailand Medical News  Oct 25, 2019  4 years, 11 months, 2 weeks, 4 days, 16 hours, 51 minutes ago

Rheumatic Patients Taking Interleukin Inhibitors At Risk Of Increased Infection And Cancer

Rheumatic Patients Taking Interleukin Inhibitors At Risk Of Increased Infection And Cancer
Source: Thailand Medical News  Oct 25, 2019  4 years, 11 months, 2 weeks, 4 days, 16 hours, 51 minutes ago
A new meta analytic study by medical researchers from the University of Arizona, Tucson indicate that patients with rheumatic diseases that are treated with interleukin inhibitors have increased risk of serious infections, opportunistic infections, and cancer.



Dr Jawad Bilal from the University of Arizona, Tucson, co-author of the study told Thailand Medical News, “These findings can inform shared decision-making when patients and clinicians are contemplating the use of interleukin inhibitors.”

To investigate these risks, study authors searched various databases for clinical trials evaluating interleukin therapy vs placebo in patients with rheumatic diseases in which safety data were reported. They identified 74 studies that included 29,214 patients; treatments evaluated in these studies included tocilizumab (18 trials), secukinumab (15 trials), anakinra (8 trials), ixekizumab (6 trials), rilonacept (6 trials), sarilumab (4 trials), sirukumab (4 trials), ustekinumab (4 trials), brodalumab (3 trials), guselkumab (2 trials), clazakizumab (2 trials), canakinumab (1 trial), and olokizumab (1 trial).

Pooled analysis showed that treatment with interleukin inhibitors was associated with a higher risk of serious infections (infections resulting in hospitalization, use of antibiotics, or death) when compared with placebo (odds ratio [OR] 1.97; 95% CI, 1.58-2.44; P <.001; I2 = 0%; high certainty). Moreover, the risk of opportunistic infection was found to be increased with interleukin inhibitors vs placebo (OR 2.35; 95% CI, 1.09-5.05; P =.03; I2 = 0%; moderate certainty).

In addition, study data showed an increased risk of cancer in patients with rheumatic diseases treated with interleukin inhibitors (OR 1.52; 95% CI, 1.05-2.19; =.03; I2 = 11%; moderate certainty). “The findings in our study suggest that the risk of cancer may be increased with longer [interleukin] inhibitor therapy,” the study authors added.

Based on their findings, the authors concluded that infection risk with interleukin inhibitors appears to be comparable to what has been observed with other biologic therapies (ie, tumor necrosis factor inhibitors), while real-world data are needed to confirm the potential for increased cancer risk with long-term therapy.

Neverthel ess, they say that the possibility of increased cancer risk with long-term IL inhibitor use should be taken into consideration.

Patients currently on these drugs are advised to consult their doctors before making any attempts to stop or switch drugs.

Reference: Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis. Bilal J, Berlinberg A, Riaz IB, Faridi W, Bhattacharjee S, Ortega G, Murad MH, Wang Z, Prokop LJ, Alhifany AA, Kwoh CK1. JAMA Netw Open. 2019 Oct 2;2(10):e1913102. doi: 10.1001/jamanetworkopen.2019.13102. https://www.ncbi.nlm.nih.gov/pubmed/31626313
 

MOST READ

Jul 25, 2024  3 months ago
Nikhil Prasad
Jul 24, 2024  3 months ago
Nikhil Prasad
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Sep 08, 2022  2 years ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation